Navigation Links
ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
Date:10/8/2009

enerate a real-time image of the prostate that physicians can use to visualize and document abnormalities in the prostate in patients identified as potentially having prostate abnormalities on digital rectal examination."

More details on the study's purpose, population, criteria and investigators is available at: http://www.clinicaltrials.gov/ct2/show/NCT00822952?term=Prostate+Mechanical+Imaging&rank=1

The ProUroScan imaging system is designed to complement the DRE, and to provide patients with potential prostate abnormalities the ability to have their prostates imaged in real time with records electronically stored for later comparison.

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is now in clinical trials for the mapping of prostate abnormalities detected by DRE. Based in Minneapolis, Minn., ProUroCare is traded on the OTCBB market.

Safe Harbor Statement

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by Pro
'/>"/>

SOURCE ProUroCare Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ProUroCare Medical Inc. Announces Pricing of Equity Offering
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Verathon®, maker of ... announce that portable bladder volume ultrasound is ... guidelines for the Prevention of Catheter-Associated Urinary ... guidelines, introduced in early November 2009, replace ... 1981. The guidelines are located on ...
(Date:12/16/2009)... Medical Technologies, Inc. today announced that its fully ... and interoperability solution, Prime Suite® 2011, won ... 2009 Top 20 Best in KLAS Awards: ... For practices having between six and 25 physicians, ... KLAS in ambulatory EMR for the fourth consecutive ...
(Date:12/16/2009)... BioSpecifics Technologies Corp. (Nasdaq: BSTC ... collagenase-based products, today announced top-line efficacy and safety ... XIAFLEX(TM) for the treatment of Peyronie,s disease. Peyronie,s ... collagen on the shaft of the penis, which ... difficult or impossible in advanced cases. The Phase ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 1Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 2Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 4MarketsandMarkets 3A Global Biosimilars Product Market Worth 2419 4 Billion by 2014 13795 1MarketsandMarkets 3A Global Biosimilars Product Market Worth 2419 4 Billion by 2014 13795 2MarketsandMarkets 3A Global Biosimilars Product Market Worth 2419 4 Billion by 2014 13795 3New Technique Offers Hope for Kids With Immune Deficiency 55986 1New Technique Offers Hope for Kids With Immune Deficiency 55986 2
... within 2-6 hours of the first dose, according to published ... RAPAFLO (TM) (silodosin), a new, uniquely selective alpha ... BPH, produces rapid improvements of both irritative and obstructive urinary ... published in the June issue of The ...
... - Glivec(R) (imatinib) Now Approved in the UK for ... are at Significant Risk of the Cancer Returning After Surgery(1) ... Surgery Significantly Reduces Risk of Cancer,Relapse(2) , ... Experience Their,Cancer Returning Within Two Years(3,4) , ...
Other Medicine Technology:RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days 2RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days 3RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days 4RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 2Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 3Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 4Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 6
(Date:12/16/2009)... If proposed health care legislation is enacted, it ... system. Approximately 18.4 million Californians and 161 million ... employer-based insurance for their health care coverage. ... legislation entail specific requirements for employer-based insurance. ... firms that currently comply with most new standards, ...
(Date:12/16/2009)... Raises Significant Funds to Benefit of Children with Autism ... Taylor, Gary Cole and Zachary Levi Join Ben Stiller ... ANGELES, Dec. 16 At its 13th annual ... individuals. Hasbro President & CEO Brian ... in recognition of his far-reaching philanthropic leadership and commitment ...
(Date:12/16/2009)... -- Immucor, Inc. (Nasdaq: BLUD ), a global ... transfusion industry, today announced that Paul D. Mintz, M.D. ... independent director, effective January 1, 2010. ,, Dr. ... medicine for more than 30 years. He is a ... of Virginia School of Medicine. He also serves as ...
(Date:12/16/2009)... The most widely used human embryonic stem cell ... justice questions that must be addressed to ensure that ... according to a University of Michigan research team. ,, ... U-M team analyzed 47 embryonic stem cell lines, including ... researchers. The scientists determined the genetic ancestry of each ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
Breaking Medicine News(10 mins):Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:Leprosy Genes Identified 2
... Hospital, Bangalore, have removed a large cancerous tumour from a ... statement that Prabhu Ram was diagnosed to be ailing from ... to difficulty in breathing, high fever and swelling of the ... arising from both the upper chambers of the heart, blocking ...
... Grunenthal GmbH presented the first clinical evidence for ... release) for patients suffering from chronic pain ... Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. ... of its kind, combining two analgesic principles, mu-receptor ...
... Medicine have identified proteins in the rod and cones of ... genetic causes of a host of inherited eye diseases. ... goes wrong at the most basic level in these diseases ... have identified and measured the types and amounts of proteins ...
... protection from harmful rays emitted by the sun and people ... may even risk blindness, warn scientists in Britain. ,The ... radiation may severely affect the skin, eyes or the immune ... choose sunglasses purely on the basis of their price and ...
... pub hopes to benefit from the ban on smoking and ... the success of the ban. The Smoking ban, in public ... ample support from the public of Britain. Three quarter of ... looking for an opening in areas where smokers are most ...
... Dietary supplements pills, liquids or other products are ... is not exactly well-regulated. ,But now, addressing concerns ... supplements, the Food and Drug Administration has announced that it ... of all ingredients by the manufacturers themselves. ,Frequently ...
Other Medicine News:Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 3Health News:Genetic Cause of Inherited Eye Diseases Identified 2Health News:Wear Protective Sunglasses, Not Just for Style 2Health News:Pubs Propose to Sell Nicotine Gum Patches 2Health News:US FDA Wants Vitamin Manufacturers to Test All Ingredients 2
... Liquichek™ Reticulocyte Stain is ... stain for use in manual ... liquid product has a one ... at 230C and can be ...
Seroconversion and Antigen Panel Chart...
... CT/GC Controls are liquid controls ... of test procedures that detect ... Since they are specimen specific, ... either urine or endocervical/urethral swabs ...
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: